Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858444 | 1.00 | JAK2 (0.48) | JAK2JAK1TYK2ROCK2ROCK1 | |
| SCHEMBL2858448 | 1.00 | JAK2 (0.48) | JAK2JAK1TYK2ROCK2ROCK1 | |
| Bromide SCHEMBL5956520 | 0.99 | JAK2 (0.48) | JAK2JAK1TYK2ROCK2ROCK1 | |
| SCHEMBL4446202 | 0.89 | ROCK2 (0.46) | JAK2JAK1TYK2ROCK2ROCK1 | |
| SCHEMBL2847238 | 0.89 | ROCK2 (0.46) | JAK2JAK1TYK2ROCK2ROCK1 | |
| SCHEMBL2847235 | 0.89 | ROCK2 (0.46) | JAK2JAK1TYK2ROCK2ROCK1 | |
| Bromide SCHEMBL5956696 | 0.88 | ROCK2 (0.45) | JAK2JAK1TYK2ROCK2ROCK1 | |
| SCHEMBL4443777 | 0.86 | PAK1 (0.35) | JAK2JAK1TYK2ROCK2IRAK4 | |
| SCHEMBL4442259 | 0.86 | PAK1 (0.35) | JAK2JAK1TYK2ROCK2IRAK4 | |
| SCHEMBL4443901 | 0.86 | PAK1 (0.35) | JAK2JAK1TYK2ROCK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | JAK2 585/4885JAK1 490/4885TYK2 354/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | JAK2 460/4885JAK1 438/4885TYK2 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.